D
iabetic individuals have a significantly higher risk for atherosclerosis than do nondiabetic individuals. 1 Persons with type 2 diabetes have significantly increased serum triglyceride (TG) and decreased HDL cholesterol concentrations. High plasma TG concentrations among diabetic subjects appear to be an independent predictive factor of mortality from coronary artery disease (CAD). 2 Over the last decade, the abnormal HDL composition in type 2 diabetes has been well studied and is characterized by TG enrichment, cholesterol depletion, and decreased apo A-I concentrations. [3] [4] [5] [6] In subjects with type 2 diabetes, total serum TG concentrations were found to be inversely correlated with HDL cholesterol and positively correlated with HDL-TG concentrations. 6 Such abnormalities in HDL might contribute to the well-established high risk for atherosclerosis in diabetes.
Type 2 diabetic subjects also have a decreased lipoprotein lipase activity 7 that might cause decreased clearance of TG-rich lipoproteins, leading to accumulation of these lipoproteins in the plasma. Elevated levels of TG-rich lipoproteins may increase the cholesteryl ester transfer protein (CETP) activity 8 that may in turn cause TG enrichment of HDL at the expense of core cholesteryl esters. 9, 10 Increased CETP activity has been reported in type 2 diabetes. 10, 11 In type 2 diabetic subjects, enhanced LDL oxidation occurs in vivo, since high titers of autoantibodies to oxidatively modified LDL are present in the plasma. 12 Oxidative modification of LDL appears central to foam cell formation, the earliest lesion of atherosclerosis. 13 HDL may protect from cardiovascular disease by a number of mechanisms, 1 of which is by inhibiting LDL oxidation in the subendothelial space. 14 -16 HDL prevents the formation of minimally modified LDL in cocultures of artery wall cells by facilitating hydrolysis of active, oxidized phospholipids to lysophospholipids, thereby destroying the biologically active lipids in minimally modified LDL. 17 Platelet-activating factor acetylhydrolase (PAF-AH) and paraoxonase (PON) are 2 enzymes associated with HDL that are known to protect LDL from oxidation. 15, 16, 18 Cavallero and colleagues 19 showed that LpA-I (HDL containing only apo A-I) isolated from subjects with non-insulindependent diabetes mellitus (NIDDM) exhibited a decreased capacity to induce cholesterol efflux in both the fasting and postprandial state and hence, had a decreased ability to accomplish their antiatherogenic role. The ability of compositionally abnormal HDL particles from type 2 diabetic subjects to perform their antiatherogenic function of protecting LDL against oxidation has not been critically examined. In our study, we examined the protection exhibited by HDL 2 and HDL 3 from subjects with poorly controlled type 2 diabetes against macrophage-mediated oxidation of LDL compared with nondiabetic healthy controls. We found that the HDL 2 subfraction from diabetic subjects was abnormal in composition, as previously reported, [3] [4] [5] [6] and also exhibited decreased protection against LDL oxidation when compared with controls.
Methods

Materials
Total cholesterol and free cholesterol kits (COD-PAP) and the total phospholipid kit (phospholipids B) were purchased from Wako Chemicals. 1-Palmitoyl-2-[(7-nitrobenzoxadiazoyl)amino]caproyl phosphatidylcholine (C 6 NBD PC) was purchased from Avanti Polar Lipids. Rabbit anti-human apo A-I and goat anti-human apo A-II were purchased from Calbiochem. Electrophoresis reagents were purchased from Bio-Rad. FCS, phorbol 12-myristate 13-acetate, peroxidase-conjugated anti-rabbit IgG and anti-goat IgG, paraoxon, glucose enzymatic kit (glucose oxidase), and the TG enzymatic kit (INT reagent) were purchased from Sigma Chemical Co.
Study Protocol
Subjects
Ten poorly controlled type 2 diabetic men who had serum cholesterol concentrations Յ240 mg/dL and serum TG concentrations Յ300 mg/dL were recruited from the Veterans Administration outpatient clinic, and 10 matched male control subjects were also recruited from the Veterans Administration Medical Center and University of Kentucky Medical Center staff. Nine subjects were white and 1 was African-American in each group. Medications taken by the diabetic subjects at the time of the study were as follows: sulfonylurea (all 10 subjects), biguanide (3 subjects), nitrates (4 subjects), loop diuretics (3 subjects), ␤-blockers (2 subjects), ␣-blockers (1 subject), and angiotensin-converting enzyme inhibitors (5 subjects). Two of the diabetic subjects had no diabetic complications, 1 subject had cerebral artery occlusion, 4 subjects had CAD, and 3 subjects had hypertension. Except for 1 diabetic subject who smoked Ͻ 1 ⁄2 pack of cigarettes per day, all other subjects were nonsmokers. None of the subjects took any antioxidant supplements or probucol.
Test Meal
We gave our subjects a fat load to see whether there was any difference between fasting and postprandial HDLs in their antiatherogenic role of protecting LDL against oxidation. Each individual arrived at 8 AM after an overnight fast. Fifty milliliters of blood was collected for lipid analysis and lipoprotein separation from serum. Immediately after the blood was drawn, the test meal was ingested within 10 minutes. The test meal consisted of 2 bowls of cornflakes, a half pint of whole milk, a half pint of whipping cream, and 2 teaspoons of granulated sugar. This meal provided Ϸ80 g of fat and 900 calories. During the next 6 hours, the patients were told not to consume any food or drink other than water or unsweetened black coffee or tea. Fifty milliliters of blood was collected 6 hours after ingestion of the test meal for lipoprotein isolation and lipid analysis. The test meal was well tolerated by all of the subjects except 1 of the diabetic subjects, who experienced nausea and vomiting.
Serum Measurements
Serum glucose concentrations were determined by using an enzymatic kit (glucose oxidase). Glycosylated hemoglobin (HbA 1c ) values were determined with an ion-exchange mini-column chromatographic procedure (Bio-Rad Laboratories); normal values are 4.2% to 6.4%. Total cholesterol was measured with an enzymatic kit from Wako Chemicals (COD-PAP) and total TGs by an enzymatic kit from Sigma (INT reagent). HDL cholesterol was quantitated after precipitation of apo B-containing lipoproteins with magnesium/ phosphotungstic acid. HDL 3 cholesterol was quantitated after a dual-precipitation method with combinations of magnesium/phosphotungstic acid and dextran sulfate. HDL 2 cholesterol was calculated as the difference between total HDL cholesterol and HDL 3 cholesterol. 20 LDL cholesterol was calculated by the Friedewald formula. 21 
LDL and HDL Subfraction Preparation
HDLs from the study subjects and LDL from a healthy donor were isolated by sequential ultracentrifugation. 22 LDL was isolated from the same healthy donor for every oxidation experiment. In brief, the density of serum was adjusted to 1.09 g/mL and centrifuged for 11 hours, 15 minutes at 50 000 rpm in a VTi50 rotor at 4°C. To isolate LDL, the density of the VLDL-LDL fraction was adjusted to 1.3 g/mL, and gradient ultracentrifugation was carried out at 50 000 rpm for 2.5 hours at 4°C. To isolate HDL, the density of the bottom fraction was adjusted to 1.25 g/mL with solid KBr and centrifuged in a VTi50 rotor at 50 000 rpm for 20 hours at 4°C. Gradient ultracentrifugation was carried out at 4°C for 15 hours at 50 000 rpm for fractionation of HDL. 23 LDL, HDL 2 , and HDL 3 were dialyzed extensively overnight against 3 changes of PBS (pH 7.4), sterilized through a 0.45-m-filter unit (Millipore), and stored at 4°C under N 2 . Aliquots of HDL subfractions were frozen at Ϫ70°C for analysis of HDL phospholipid, cholesteryl ester, and free cholesterol concentrations.
HDL Subfraction Composition
Total cholesterol and free cholesterol concentrations were measured by enzymatic methods with the use of commercially available kits (COD-PAP), and cholesteryl esters were calculated as the difference between total and free cholesterol. TG concentrations were determined by using an enzymatic kit (INT reagent). Total phospholipids were measured by an enzymatic method that uses phospholipase D-choline oxidase and peroxidase (phospholipids B).
Total protein contents of the HDL subfractions were measured by the Lowry method. 24 Apo A-I and A-II in HDL subfractions were quantitated by SDS-polyacrylamide gradient gel electrophoresis (PAGE) followed by Western blotting. 23 In brief, electrophoresis was carried out on a 5% to 20% acrylamide/SDS gel and a 25 mmol/L Tris, 192 mmol/L glycine electrophoresis buffer (pH 8.4) containing 0.1% SDS. 23 The proteins were transferred onto a 0.2-m nitrocellulose membrane by using a 25 mmol/L Tris, 192 mmol/L glycine transfer buffer (pH 8.4) containing 15% (vol/vol) methanol. 23 The blots were blocked for 1 hour with 5% (wt/vol) nonfat dry milk in PBS (pH 7.4). The blots were then exposed to the primary and secondary antibodies for 1 hour each. The primary antibody for apo A-I was rabbit anti-human apo A-I, and for apo A-II, goat anti-human apo A-II. The secondary antibody was a peroxidaseconjugated anti-rabbit IgG and anti-goat IgG, respectively. The antibodies were then detected with the enhanced chemiluminescence (ECL) detection reagents (Amersham), and the blots were exposed to x-ray film. The bands were scanned with a densitometer.
HDL Subfraction Enzyme Activities
PON and PAF-AH activities were measured in fresh HDL samples within 2 days of isolation. HDL PON activity was measured with a 1.0 mmol/L paraoxon substrate in 50 mmol/L Tris-HCl buffer (pH 7.4) containing 1.0 mmol/L CaCl 2 in a total volume of 800 L. 25 One hundred micrograms of HDL 2 or HDL 3 was added to start the reaction, and the increase in absorbance at 412 nm was recorded continuously for 10 minutes. The amount of 4-nitrophenol formed was calculated from the molar extinction coefficient of 12 800 M Ϫ1 cm
Ϫ1
. The blank contained substrate without HDL. One unit of PON activity is defined as 1 nmol of 4-nitrophenol formed per minute under the above assay conditions. PAF-AH activity was measured by using a fluorescent substrate, C 6 NBD PC, by a modification of the method of Steinbrecher and Pritchard. 26 Four micromoles of the substrate C 6 NBD PC was incubated with 10 g of HDL 2 or HDL 3 protein in 1 mL of PBS (pH 7.4) at 37°C for 90 minutes. The reaction was terminated by vortexing with 1 mL of methanol and 1 mL of chloroform for Ϸ1 minute, and the mixture was then centrifuged at 2500g for 10 minutes. The fluorescence of the aqueous phase was measured at 470 nm excitation and 533 nm emission in a fluorospectrometer. The mass of fluorescent substrate hydrolyzed was calculated by using a standard curve generated by using C 6 NBD fatty acid diluted in methanol.
Cell Culture
Dr Mark Kindy (Department of Biochemistry) provided the THP-1 monocytic cells. THP-1 cells were grown in suspension in RPMI-1640 medium containing 10% FCS, 100 U/mL streptomycin, and 100 U/mL penicillin. Cells were maintained at a density of 10 6 mL
Ϫ1
by pelleting the cells twice weekly. Forty-eight hours before cellmediated oxidation studies, 2ϫ10 6 cells were seeded per well in a 12-well tissue-culture plate and induced to differentiate into macrophages by the addition of 10 Ϫ7 mol/L phorbol 12-myristate 13-acetate. 27 
Macrophage-Mediated Oxidation of Lipoproteins
The differentiated macrophages were washed 3 times with PBS before incubation with lipoproteins. Macrophage cells were incubated with 100 g of LDL protein, with or without 100 g of HDL 2 or HDL 3 protein, in 1 mL of serum-free Ham's F-10 medium containing gentamicin (50 g/mL) at 37°C in a 5% CO 2 incubator for 24 hours. 28 Additionally, 100 g of HDL 2 or HDL 3 protein was incubated separately with the cells. Oxidation was arrested after 24 hours by the addition of 200 mol/L EDTA and 20 mol/L BHT, and the medium was spun at 1200 rpm for 5 minutes at 4°C. Aliquots of the medium were used for determining lipid peroxides, electrophoretic mobility, apo B-100 fragmentation in LDL, and apo A-I cross-linking in HDL subfractions.
Assessment of Oxidative Damage
Lipid peroxides in the oxidized lipoproteins were determined by mixing 0.1 mL of the medium containing the modified lipoproteins with 1.0 mL of iodine-color reagent, incubating the mixture for 30 minutes at room temperature in the dark, and reading the absorbance at 365 nm. 29 The concentration of lipid peroxides was calculated using a molar absorption coefficient of 2.46ϫ10 4 M Ϫ1 cm Ϫ1 . Lipid peroxides present in HDL samples oxidized separately were used as a correction factor for the lipid peroxides formed in the LDL samples containing HDL during oxidation.
Electrophoretic mobility was determined using 1.0% agarose gels. Oxidized LDL was subjected to electrophoresis in 0.05 mol/L barbital buffer (pH 8.6) at 90 V for 45 minutes. 30 The gel was dried and stained in Sudan black B. Electrophoretic mobility was measured as the distance from the origin to the median point of the lipoprotein peak distribution. The increase in the electrophoretic mobility of each oxidized LDL sample was calculated as a relative ratio to that of native LDL and expressed as relative electrophoretic mobility.
Apo B-100 Fragmentation
Fragmentation and aggregation of apo B-100 in the medium containing 1 g of LDL, oxidized in the absence or presence of HDL 2 or HDL 3 , was determined using 5% to 20% SDS-polyacrylamide gradient gels under reducing conditions as detailed above. The gels were fixed for 1 hour and stained with AgNO 3 (Bio-Rad).
Apo A-I Cross-Linking
Apolipoprotein A-I cross-linking in macrophage-modified HDL 2 or HDL 3 was determined by subjecting the medium containing 1 g of HDL protein to SDS-PAGE under reducing conditions, 23 followed by Western blotting with an antibody against apo A-I.
Data Analysis
Statistical analysis for comparison between groups was performed using a 2-way ANOVA followed by post hoc testing with Tukey's multiple comparisons test by using SYSTAT statistics software. 31 Results are expressed as meanϮSEM. Correlation coefficients were determined by simple linear regression analysis. Values of PϽ0.05 were considered to be statistically significant. Table 1 provides the clinical characteristics and also the serum lipid profiles of the diabetic and control subjects in both the fasting and postprandial states. The diabetic subjects were poorly controlled and had high HbA 1c and fasting serum glucose concentrations. Although body mass index did not differ between the diabetic and control subjects, the diabetic subjects were significantly older (PϽ0.002). Diabetic and control subjects had similar serum total and LDL cholesterol concentrations. Diabetic subjects had slightly but not significantly higher serum TG concentrations, compared with controls, in both the fasting and postprandial states. However, HDL cholesterol and HDL 2 cholesterol concentrations were significantly decreased in the diabetics in both the fasting (PϽ0.01) and postprandial (PϽ0.005) states. Serum TG concentrations were significantly increased postprandially after a fat load in both the control (Pϭ0.014) and diabetic (Pϭ0.001) subjects. Table 2 illustrates composition of HDL 2 and HDL 3 from control and diabetic subjects. Two-way ANOVA indicated that diabetic subjects exhibited significant compositional abnormalities in their HDL 2 fraction in both fasting and postprandial states compared with controls. Diabetics had (1) a decrease in HDL 2 free cholesterol concentrations and (2) an increase in HDL 2 -TG concentrations in both fasting (PϽ0.05) and postprandial (PϽ0.05) states compared with controls. Apo A-I concentrations were significantly decreased in HDL 2 from diabetic subjects compared with controls in both fasting (PϽ0.05) and postprandial (PϽ0.05) states. There was a slight but nonsignificant increase in the HDL 2 apo A-II concentrations in diabetics compared with control subjects. PAF-AH and PON activities in HDL 2 were not significantly different between control and diabetic subjects.
Results
Subject Characteristics
Composition of HDL 2 and HDL 3
Two-way ANOVA indicated that the only significant differences in HDL 3 composition were associated with the high-fat meal and not due to diabetes. We found no difference in the HDL 3 composition between the control and diabetic subjects. In both control and diabetic subjects, HDL 3 had a significant increase in proteins (PϽ0.01) and phospholipids (PϽ0.05) but a significant decrease in cholesteryl esters (PϽ0.01) postprandially compared with the fasting state. Free cholesterol concentrations in HDL 3 were significantly increased in the postprandial state (PϽ0.05) in control but not in diabetic subjects. There was no significant difference in either apo A-I and A-II concentrations or PON and PAF-AH activities in HDL 3 from control and diabetic subjects. Figure 1 illustrates lipid peroxide accumulation in LDL oxidized in the absence and presence of HDL 2 Figure 3 illustrates the fragmentation of apo B-100 in LDL when oxidized in the absence or presence of HDL 2 from control and diabetic subjects. HDL 2 from control subjects, in both fasting and postprandial states, protected the apo B-100 in LDL from fragmentation during oxidation to a significant extent. However, the apo B-100 band in LDL oxidized in the presence of HDL 2 from diabetic subjects was almost completely fragmented. Figure 4 illustrates that HDL 2 from controls, when oxidized in the presence of LDL, had only minimal apo A-I crosslinking in the fasting state, which was amplified in the postprandial state. However, both fasting and postprandial HDL 2 from diabetic subjects, oxidized in the presence of LDL, showed extensive apo A-I cross-linking when compared with control HDL 2 .
Protection Against Macrophage-Mediated LDL Oxidation
Linear Regression Analysis
Simple linear regression analysis was performed to assess which components in the control and diabetic HDL 2 might be associated with their protective effects against LDL oxidation. Protection by control HDL 2 against lipid peroxide accumulation in LDL was strongly and positively correlated with its associated PAF-AH activity both in the fasting (rϭ0.872, Pϭ0.002) (Figure 5a ) and postprandial (rϭ0.818, Pϭ0.007) state (data not shown), whereas diabetic HDL 2 -associated PAF-AH activity was not correlated with its protection in either the fasting (Figure 5b Correlation analysis indicated that protection by HDL 2 from control subjects against lipid peroxide accumulation in LDL was not correlated with serum TG, HDL 2 -TG, cholesterol, phospholipid, or apoprotein concentrations. In contrast, protection by HDL 2 from diabetic subjects was inversely correlated with serum TG concentrations in both the fasting (rϭϪ0.673, PϽ0.05) and postprandial (rϭϪ0.798, PϽ0.02) states (Figure 6a and 6b) . Similarly, protection by HDL 2 from lipid peroxide accumulation in the diabetic subjects in the fasting state was inversely correlated with HDL 2 -TG concentration (rϭϪ0.636, PϽ0.05) (Figure 6c ) and positively correlated with HDL 2 free cholesterol concentration (rϭ0.820, PϽ0.005) (Figure 6d ). In the diabetic subjects, we did not see any correlation between the level of glycemic control and HDL 2 and HDL 3 composition, PON and PAF-AH activities, or protection against LDL oxidation (data not shown).
Discussion
Type 2 diabetic subjects present an increased risk for CAD that is related to their degree of hypertriglyceridemia. 3 Compositional abnormalities in HDL are well characterized in NIDDM. [3] [4] [5] [6] To determine whether abnormal HDL particles in NIDDM are able to maintain antiatherogenic functions, we examined the protective effects of HDL 2 and HDL 3 from poorly controlled type 2 diabetic and nondiabetic control subjects in both fasting and postprandial states against macrophage-mediated LDL oxidation.
Control subjects had a slight increase in phospholipid, free cholesterol, and protein concentrations in both HDL 2 and HDL 3 postprandially compared with the fasting state. Alimentary lipemia resulted in an increase in concentrations of phospholipids and proteins in HDL, particularly in the HDL 2 subfraction. 32 The magnitude of postprandial lipemia determines the proportion of TGs in postprandial HDL 2 . 33 In our study, HDL 2 from diabetic subjects were enriched in TGs and depleted of free cholesterol and apo A-I compared with that in controls. Other studies 34, 35 reported similar compositional abnormalities in type 2 diabetes. Similar to our results, Cavallero et al 3 reported a significant postprandial decrease in free cholesterol and cholesteryl ester concentrations and an increase in TG concentrations in HDL 2 from type 2 diabetics. Increased cholesteryl ester transfer rates mediated by CETP in type 2 diabetes 10,11,36 appear important for the TG enrichment and cholesterol depletion seen in HDL 2 . In the diabetic subjects, we found a positive correlation between serum TG concentrations and HDL 2 -TG concentrations (data not shown), as previously reported by Biesbroeck and colleagues. 6 Postprandially, we found a significant TG enrichment of HDL 2 in diabetic subjects only, although both control and diabetic subjects had significant increases in their serum TG concentrations postprandially compared with the fasting state. Abbott et al 37 have shown that serum PON activity is lower in type 2 diabetic subjects than in controls. However, we did not see a significant difference in HDL PON or PAF-AH activity between diabetic and control subjects.
Effects of the individual HDL 2 and HDL 3 subfractions against LDL oxidation in relation to their PAF-AH and PON activities are poorly understood. When we examined the protective effects of HDL subfractions against LDL oxidation from control subjects, HDL 2 was significantly more efficient than HDL 3 in inhibiting LDL oxidation in all parameters assayed. Navab and colleagues 38 have shown that virtually all HDL-mediated inhibition of monocyte transmigration induced by minimally modified LDL can be accounted for by HDL 2 , whereas HDL 3 had no effect. The greater protective effect of HDL 2 seen in our study may be due to a higher PAF-AH activity associated with HDL 2 compared with HDL 3 . In our study, HDL 2 and HDL 3 were not good substrates for macrophage oxidation compared with LDL. This may be due to a decreased lipid content in HDL. Other studies have also shown that unlike LDL, HDL is not susceptible to modification by endothelial cells 14 or in cocultures of artery wall cells. 38 In comparing the protective effects of HDL from control and diabetic subjects against LDL oxidation, no differences between HDL 3 from control and diabetic subjects were observed. On the other hand, HDL 2 fractions from diabetic subjects exhibited decreased protection against LDL oxidation compared with controls in both fasting and postprandial states in most of the parameters assayed. There was increased lipid peroxide accumulation and electrophoretic mobility; also, their apo B-100 was almost completely fragmented when LDL was oxidized in the presence of HDL 2 from diabetic compared with control subjects. In controls, in both fasting and postprandial states, HDL 2 exhibited significantly greater protection compared with HDL 3 , but this difference between HDL 2 and HDL 3 was not seen in diabetic subjects. This suggests that HDL 2 from diabetic subjects may have lost its efficiency to protect LDL from oxidation. Correlation analysis indicated that the increase in serum TG concentrations might mediate these effects by altering the composition of HDL 2 . Decreased free cholesterol and increased TG concentrations in HDL 2 from diabetic subjects may contribute importantly to the decreased protection exhibited by diabetic HDL 2 .
Of importance, TG-enriched HDL 2 from diabetic subjects, though not susceptible to oxidation, exhibited decreased protection against LDL oxidation compared with HDL 2 from controls. To determine whether diabetic HDL 2 was being more structurally altered in the presence of LDL compared with control HDL 2 , we studied the apo A-I cross-linking in HDL 2 . When HDL 2 was oxidized in the presence of LDL, there was more extensive apo A-I cross-linking in HDL 2 from diabetic subjects compared with controls. The greater apo A-I cross-linking seen in HDL 2 from diabetic subjects compared with controls, when oxidized along with LDL, suggests that compositionally altered diabetic HDL 2 may not be as efficient as control HDL 2 in inhibiting lipid peroxide generation in LDL. Therefore, the large amounts of aldehydes formed during LDL oxidation may have modified the apo A-I in diabetic HDL 2 . Aldehydes such as 4-hydroxynonenal and malondialdehyde generated during LDL oxidation can cause apo A-I cross-linking in HDL. 39 Two possible mechanisms for the decreased protection exhibited by HDL 2 from diabetic subjects include the following: (1) The decreased free cholesterol concentration seen in diabetic HDL 2 may alter its surface fluidity, perhaps thereby facilitating the lipid peroxides generated during LDL oxidation to "seed" the HDL 2 . Once seeded with lipid peroxides, the TG-enriched HDL 2 from diabetic subjects may be more susceptible to oxidation and become less protective. (2) The lipid peroxidation products transferred from oxidized LDL may directly inactivate the PAF-AH activity in HDL 2 . Dentan and colleagues 40 have demonstrated that 4-hydroxynonenal generated during LDL oxidation may inhibit PAF-AH activity, either by a direct modification of amino acid side chains in PAF-AH or by a modification of the phospholipid environment of the enzyme at the surface of the lipoprotein particle. In conclusion, our study demonstrates that HDL 2 from subjects with poorly controlled NIDDM, in both fasting and postprandial states, exhibits decreased protection against macrophage-mediated LDL oxidation, and this may contribute to accelerated atherosclerosis in type 2 diabetes.
